BR112022022004A2 - Complexo proteico, método para preparar um complexo proteico, composição farmacêutica para prevenir ou tratar câncer, uso da composição e uso do completo proteico - Google Patents

Complexo proteico, método para preparar um complexo proteico, composição farmacêutica para prevenir ou tratar câncer, uso da composição e uso do completo proteico

Info

Publication number
BR112022022004A2
BR112022022004A2 BR112022022004A BR112022022004A BR112022022004A2 BR 112022022004 A2 BR112022022004 A2 BR 112022022004A2 BR 112022022004 A BR112022022004 A BR 112022022004A BR 112022022004 A BR112022022004 A BR 112022022004A BR 112022022004 A2 BR112022022004 A2 BR 112022022004A2
Authority
BR
Brazil
Prior art keywords
protein complex
composition
pharmaceutical composition
preparing
preventing
Prior art date
Application number
BR112022022004A
Other languages
English (en)
Inventor
Youb Jung Sung
Jin Park Young
Joo Bang Hyo
Sup Kim Maeng
Original Assignee
Mustbio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mustbio Co Ltd filed Critical Mustbio Co Ltd
Publication of BR112022022004A2 publication Critical patent/BR112022022004A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

COMPLEXO PROTEICO, MÉTODO PARA PREPARAR UM COMPLEXO PROTEICO, COMPOSIÇÃO FARMACÊUTICA PARA PREVENIR OU TRATAR CÂNCER, USO DA COMPOSIÇÃO E USO DO COMPLEXO PROTEICO. A presente invenção fornece: um complexo proteico que tem uma alta taxa de formação de heterodímero; um método de preparação para o mesmo; uma composição farmacêutica para prevenir ou tratar câncer, que contém o complexo proteico; e um método para prevenir ou tratar câncer usando-se a composição. De acordo com a presente invenção, um anticorpo biespecífico ou um fragmento de ligação ao antígeno com maior estabilidade, um receptor e um agonista de ligação ao receptor, antagonista, ligante, citocina ou biconjugado de receptor isca podem ser facilmente preparados e utilizados em vários campos, como na prevenção ou tratamento de doenças e no diagnóstico de doenças.
BR112022022004A 2020-06-01 2021-05-28 Complexo proteico, método para preparar um complexo proteico, composição farmacêutica para prevenir ou tratar câncer, uso da composição e uso do completo proteico BR112022022004A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200066030 2020-06-01
PCT/KR2021/006643 WO2021246720A1 (ko) 2020-06-01 2021-05-28 이중특이 항체 또는 그의 항원-결합 단편 및 이를 제조하는 방법

Publications (1)

Publication Number Publication Date
BR112022022004A2 true BR112022022004A2 (pt) 2022-12-13

Family

ID=78831197

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022022004A BR112022022004A2 (pt) 2020-06-01 2021-05-28 Complexo proteico, método para preparar um complexo proteico, composição farmacêutica para prevenir ou tratar câncer, uso da composição e uso do completo proteico

Country Status (11)

Country Link
US (1) US20230212320A1 (pt)
EP (1) EP4159765A1 (pt)
JP (1) JP2023534773A (pt)
KR (2) KR102365669B1 (pt)
CN (1) CN115698086A (pt)
AU (1) AU2021282817A1 (pt)
BR (1) BR112022022004A2 (pt)
CA (1) CA3177026A1 (pt)
IL (1) IL297566B1 (pt)
MX (1) MX2022013663A (pt)
WO (1) WO2021246720A1 (pt)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO2013166594A1 (en) * 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
EA032681B1 (ru) * 2012-11-27 2019-07-31 Аджоу Юниверсити Индастри-Академик Кооперейшн Фаундейшн ГЕТЕРОДИМЕР Fc ИММУНОГЛОБУЛИНА, СОДЕРЖАЩИЙ ВАРИАНТ ДОМЕНА CH3 ДЛЯ ОБРАЗОВАНИЯ АНТИТЕЛА ИЛИ ГИБРИДНОГО БЕЛКА С ГЕТЕРОМЕРНЫМ Fc С ВЫСОКОЙ ЭФФЕКТИВНОСТЬЮ, СПОСОБ ДЛЯ ЕГО ПОЛУЧЕНИЯ И ИСПОЛЬЗОВАНИЯ
MX2016005762A (es) * 2013-11-11 2016-08-19 Chugai Pharmaceutical Co Ltd Region variable de anticuerpo modificada que contiene molecula de union al antigeno.
US10538595B2 (en) * 2015-08-26 2020-01-21 Bison Therapeutics, Inc. Multispecific antibody platform and related methods
AU2017298535B2 (en) 2016-07-19 2020-12-10 Ibentrus, Inc. Bispecific proteins and methods for preparing same
CN109963871A (zh) * 2016-08-05 2019-07-02 豪夫迈·罗氏有限公司 具有激动活性的多价及多表位抗体以及使用方法
WO2018030806A1 (ko) * 2016-08-10 2018-02-15 아주대학교산학협력단 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물
MA52640A (fr) * 2018-05-16 2021-03-24 Janssen Biotech Inc Procédés de traitement de cancers et d'amélioration de l'efficacité d'agents thérapeutiques de redirection de lymphocytes t
KR20200066030A (ko) 2018-11-30 2020-06-09 (주)아틀라스랩스 음성 id 시스템을 이용한 음성 등록 및 인증방법

Also Published As

Publication number Publication date
CN115698086A (zh) 2023-02-03
IL297566A (en) 2022-12-01
KR20210148943A (ko) 2021-12-08
KR20220030224A (ko) 2022-03-10
AU2021282817A1 (en) 2022-11-17
KR102405816B1 (ko) 2022-06-08
EP4159765A1 (en) 2023-04-05
KR102365669B1 (ko) 2022-02-23
CA3177026A1 (en) 2021-12-09
JP2023534773A (ja) 2023-08-10
IL297566B1 (en) 2024-03-01
MX2022013663A (es) 2022-11-30
US20230212320A1 (en) 2023-07-06
WO2021246720A1 (ko) 2021-12-09

Similar Documents

Publication Publication Date Title
Coleman et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
Harbeck et al. HER2 dimerization inhibitor pertuzumab-mode of action and clinical data in breast cancer
Zhou et al. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non–small-cell lung cancer
Huang et al. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation
CN103533960B (zh) c-KIT抗体及其用途
Chen et al. Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis
Raja et al. Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data
BR112020016331A8 (pt) Métodos para tratar câncer com anticorpos anti-pd-1
Graeven et al. Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer
Zanardi et al. Better together: targeted combination therapies in breast cancer
Ioannou et al. Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
Ciardiello et al. Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer
Bernier et al. Molecular therapy in head and neck oncology
Petrelli et al. Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies
KR20140023921A (ko) ＥｒｂＢ 경로 저해제들에 대한 저항성을 극복하는 방법
Ibrahim et al. Cetuximab-based therapy is effective in chemotherapy-naive patients with advanced and metastatic non-small-cell lung cancer: a meta-analysis of randomized controlled trials
KR20130065655A (ko) 치료 방법
Emde et al. Simultaneous inhibition of estrogen receptor and the HER2 pathway in breast cancer: effects of HER2 abundance
JP2017535534A (ja) がんを治療するための単独または併用療法におけるｃｃｒ５拮抗剤の使用
Tolaney New HER2-positive targeting agents in clinical practice
JP2015512877A (ja) 癌を治療するためのクラステリン阻害剤とｅｇｆｒ阻害剤の併用
Nahta New developments in the treatment of HER2-positive breast cancer
Reck et al. Necitumumab plus gemcitabine and cisplatin as first-line therapy in patients with stage IV EGFR-expressing squamous non-small-cell lung cancer: German subgroup data from an open-label, randomized controlled phase 3 study (SQUIRE)
AR082353A1 (es) Ligando ox40 y de linfopoyetina del estroma timico (tslp) en el cancer
Serna-Gallegos et al. The ecstacy of gold: patent expirations for trastuzumab, bevacizumab, rituximab, and cetuximab